ORX Orexo AB (publ)
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. The company has a research collaboration with SVF Vaccines to explore AmorphOX formulation of LNP-mRNA vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Orexo (STO: ORX)
›
Orexo (STO: ORX) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 55 employees.
The shares were at 1.000 SEK on 19 November 2026, down 96.4% over 52 weeks. Its 52-week range is 0.8000 SEK to 36.00 SEK: the price is 97.2% below the high and 25.0% above the low.
Its market capitalisation is 56.09M SEK.
Orexo reports return on equity of 130.3% and revenue down 83.3% year over year.
It holds more cash than debt, a net cash position of 146.00M SEK. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 4 February 2027.